Stay updated on IDO Inhibitor+Gem/Nab-Pac in Metastatic Pancreatic Cancer Clinical Trial

Sign up to get notified when there's something new on the IDO Inhibitor+Gem/Nab-Pac in Metastatic Pancreatic Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the IDO Inhibitor+Gem/Nab-Pac in Metastatic Pancreatic Cancer Clinical Trial page

  1. Check
    2 days ago
    No Change Detected
  2. Check
    9 days ago
    Change Detected
    Summary
    Recruitment status updated to 'No longer looking for participants', indicating enrollment for this study has ended. This reflects a closure of participant recruitment.
    Difference
    0.4%
    Check dated 2026-06-14T05:09:58.000Z thumbnail image
  3. Check
    16 days ago
    Change Detected
    Summary
    Revision history updated to v3.5.5, replacing v3.5.4. This indicates an updated edition of the study documents.
    Difference
    0.0%
    Check dated 2026-06-06T23:55:49.000Z thumbnail image
  4. Check
    38 days ago
    Change Detected
    Summary
    The page now displays a new site revision tag Revision: v3.5.4, replacing the previous Revision: v3.5.3 in the footer. This reflects a routine deployment update rather than changes to study data.
    Difference
    0.0%
    Check dated 2026-05-16T10:23:11.000Z thumbnail image
  5. Check
    59 days ago
    Change Detected
    Summary
    ClinicalTrials.gov’s page footer has been updated to reflect a new site revision (v3.5.3), replacing the previous one (v3.5.2). This indicates a platform/version update rather than a change to the study record information.
    Difference
    0.0%
    Check dated 2026-04-24T22:25:56.000Z thumbnail image
  6. Check
    67 days ago
    Change Detected
    Summary
    Revision updated from v3.5.0 to v3.5.2.
    Difference
    0.0%
    Check dated 2026-04-17T14:13:12.000Z thumbnail image
  7. Check
    74 days ago
    Change Detected
    Summary
    Added Results Posted and expanded study details, including Non-Randomized design, Phase 1 and Phase 2 arms, and dosing regimens for Indoximod with Gemcitabine and Nab-Paclitaxel, along with updates to outcomes such as Overall Survival and Progression-Free Survival.
    Difference
    3%
    Check dated 2026-04-10T09:13:19.000Z thumbnail image

Stay in the know with updates to IDO Inhibitor+Gem/Nab-Pac in Metastatic Pancreatic Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the IDO Inhibitor+Gem/Nab-Pac in Metastatic Pancreatic Cancer Clinical Trial page.